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Cryptosporidium parvum is a species of protozoa that causes cryptosporidiosis, an
intestinal disease affecting many mammals including humans. Typically, in healthy
individuals, cryptosporidiosis is a self-limiting disease. However, C. parvum can cause
a severe and persistent infection that can be life-threatening for immunocompromised
individuals, such as AIDS patients. As there are no available treatments for these patients
that can cure the disease, there is an urgent need to identify treatment options. We
tested the anti-parasitic activity of the alkylphosphocholine oleylphosphocholine (OlPC),
an analog of miltefosine, against C. parvum in in vitro and in vivo studies. In vitro
experiments using C. parvum infected human ileocecal adenocarcinoma cells (HCT-8
cells) showed that OlPC has an EC50 of 18.84 nM. Moreover, no cell toxicity has been
seen at concentrations ≤50 μM. C57BL/6 interferon gamma receptor knock-out mice,
were infected by gavage with 4000 C. parvum oocysts on Day 0. Oral treatments, with
OlPC, miltefosine, paromomycin or PBS, began on Day 3 post-infection for 10 days.
Treatment with OlPC, at 40 mg/kg/day resulted in 100% survival, complete clearance
of parasite in stools and a 99.9% parasite burden reduction in the intestines at Day
30. Doses of 30 and 20 mg/kg/day also demonstrated an increased survival rate
and a dose-dependent parasite burden reduction. Mice treated with 10 mg/kg/day of
miltefosine resulted in 50% survival at Day 30. In contrast, control mice, treated with
PBS or 100 mg/kg/day of paromomycin, died or had to be euthanized between Days
6 and 13 due to severe illness. Results of parasite burden were obtained by qPCR and
cross-validated by both flow cytometry of stool oocysts and histological sections of the
ileum. Together, our results strongly support that OlPC represents a potential candidate
for the treatment of C. parvum infections in immunocompromised patients.
Keywords: Cryptosporidium parvum, cryptosporidiosis, oleylphosphocholine, OlPC, miltefosine, interferon
gamma receptor knockout mice, oocysts, parasite burden
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Introduction
Cryptosporidium parvum is an obligate parasite of the phylum
Apicomplexa that infects the microvilli of the small intestine
of many mammalian hosts including humans (Ryan and Xiao,
2014). Considered as a major waterborne pathogen (drinking
and recreational water) that can also be transmitted through
contaminated foods (Fayer et al., 2000; Cacciò and Putignani,
2014), C. parvum outbreaks have been widely reported in
numerous countries from all continents (Cacciò et al., 2005;
Putignani and Menichella, 2010; Cacciò and Putignani, 2014).
This parasite can remain infectious for months in a humid
environment (Robertson et al., 1992; King et al., 2005; Cacciò and
Putignani, 2014). As a result, C. parvum has been categorized as
a class B bioterrorist pathogen by the Center for Disease Control
and Prevention (CDC; Feldmann et al., 2002; Rotz et al., 2002).
As one of the major causative agents of cryptosporidiosis
in humans, along with Cryptosporidium hominis (Cacciò et al.,
2005), C. parvum causes self-limiting watery diarrhea or
persistent and severe diarrhea depending on the age and the
immune status of the patient (Chalmers and Davies, 2010;
Putignani and Menichella, 2010; Shikani and Weiss, 2014).
Indeed, C. parvum infection has been reported to be life-
threatening in AIDS patients, among which the prevalence
of cryptosporidiosis was determined to be 14% in developed
countries and 24% in developing countries (Collinet-Adler and
Ward, 2010; Putignani and Menichella, 2010). Cryptosporidium
spp., along with Giardia spp., has also been identiﬁed as the
leading cause of chronic or persistent diarrhea in children in
a context of malnutrition or immunodeﬁciency (Thapar and
Sanderson, 2004; Putignani and Menichella, 2010). The Global
Enteric Multicenter Study identiﬁed Cryptosporidium as one of
the top ﬁve pathogens causing mild to severe diarrhea in children
under the age of 2 in developing countries (Kotloﬀ et al., 2013).
Studies have shown that Cryptosporidium infections in young
children have often resulted in stunting and lead to poor cognitive
functions later in childhood (Berkman et al., 2002). However,
currently available treatments have demonstrated limited eﬀect
in these vulnerable populations (Mead and Arrowood, 2014).
Nitazoxanide, the only American Food and Drug
Association (FDA) approved drug to treat cryptosporidiosis
in immunocompetent patients, has shown little activity to ﬁght
against C. parvum infections in AIDS patients (Cabada and
White, 2010; Rossignol, 2010; Mead and Arrowood, 2014).
Similarly, paromomycin, the currently used drug to treat
C. parvum infections in AIDS patients, has shown modest
activity and limited results in diﬀerent case studies (Hewitt
et al., 2000; Rossignol, 2010). With no eﬃcient way to treat
immunocompromised patients, many drugs have been tested
over the years, but very few have shown consistent activity (Mead
and Arrowood, 2014).
Oleylphosphocholine (OlPC, C23H48NO4P) belongs to the
family of alkylphosphocholines (Hernandez et al., 2014) and is
structurally related to miltefosine (van Blitterswijk and Verheij,
2008), with the chemical formula C21H46NO4P · xH2O. Both
compounds have shown in vitro and in vivo anti-leishmanial
activity (Fortin et al., 2014), and in vitro activity of miltefosine
against C. parvum has also been reported (Shahiduzzaman et al.,
2009). This study reports the strong activity of OlPC, both in vitro
and in vivo in an immunocompromised C57BL/6 IFNγR-KO
mouse model of C. parvum infection.
Materials and Methods
Parasites
Cryptosporidium parvum (Iowa strain) oocysts, generously
provided by Dr. Michael J. Arrowood (CDC, Atlanta, GA, USA),
were maintained through a C57BL/6 IFNγR-KOmouse infection
model previously described by our laboratory (von Oettingen
et al., 2008). Oocysts were puriﬁed following the reported
technique (von Oettingen et al., 2008) and were stored in 2.5%
(w/v) aqueous potassium dichromate (K2Cr2O7, Sigma-Aldrich,
Oakville, ON, Canada) at 4◦C.
Test Compound
Oleylphosphocholine was generously provided by Dafra Pharma
Research and Development (Turnhout, Belgium) and stored at
4◦C, away from light. For in vitro studies, OlPC was diluted
to a stock solution of 11.5 mM in ddH2O. Miltefosine (Sigma-
Aldrich, Oakville, ON, Canada) was used as a control in the in
vitro assays because of its previously reported activity against
C. parvum (Shahiduzzaman et al., 2009). Paromomycin (Sigma-
Aldrich) was also used as a control in the in vitro assays. The
drugs were prepared fresh daily in phosphate-buﬀered saline
(PBS) for animal studies.
Host Cells
For in vitro studies, human colonic tumor cells (ileocecal
adenocarcinoma; HCT-8: ATCC CCL-244) were used. Cells
were maintained in T225 ﬂasks (BD Bioscience, Mississauga,
ON, Canada) using DMEM media (Wisent, St-Bruno, QC,
Canada). For OlPC in vitro studies, media was supplemented
with 10 μg/ml gentamycin, 10 μg/ml streptomycin, 100 U/ml
penicillin, 10% heat-inactivated fetal bovine serum (FBS), and
non-essential amino acids (NEAA; Wisent). For the cytotoxicity
assays, cells were grown in supplemented DMEMwithout phenol
red and further supplemented with 4.5 g/L D-glucose (Sigma-
Aldrich, Oakville, ON, Canada) and 110 mg/L sodium pyruvate
(Sigma-Aldrich). For miltefosine and paromomycin in vitro
studies, media was supplemented with 10 μg/ml gentamicin,
50 μg/ml streptomycin, 50 U/ml penicillin, and 10% heat-
inactivated FBS.
Cytotoxicity of OlPC in HCT-8 Cells
XTT assay (Sigma-Aldrich) was used (Roehm et al., 1991),
which relies on the ability of live cells to cleave XTT causing
a colorimetric change, to quantify the possible cytotoxicity of
OlPC in HCT-8 cells. For this assay, DMEM without phenol
red was used. Initially, 5 × 104 HCT-8 cells in 200 μL of
supplemented DMEM were seeded in a 96-well ﬂat-bottom
plates (BD Falcon, Franklin Lakes, NJ, USA) and incubated
overnight (or until they reached ∼80% conﬂuency) at 37◦C with
5% CO2. Freshly prepared serial dilutions of OlPC diluted in
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supplemented DMEM were used and 50 μL of these solutions
were added to the wells to obtain ﬁnal OlPC concentrations
ranging from 10 to 1000 μM (4.33 to 433 μg/mL). Samples were
run in quadruplicate and plates were incubated at 37◦C with
5% CO2 for 48 h. Then, 50 μL of XTT (dissolved in DMEM)
was added to each well and plates were re-incubated for 4 h.
Absorbance was measured at 450 nm using a plate reader (EL800
BioTek; Fisher, Nepean, ON, Canada).
C. parvum Infection Model in HCT-8 Cells
We tested the eﬀect of OlPC on C. parvum sporozoites in
HCT-8 cells. Brieﬂy, 24-well ﬂat-bottom plates (BD Falcon)
were seeded with 3 × 105 cells in 1.4 mL of supplemented
DMEM and incubated overnight (or until they reached ∼80%
conﬂuency) at 37◦C with 5% CO2. Stock oocysts in 2.5%
K2Cr2O7 were washed three times with 0.1 M acetate-NaCl
buﬀer, pH 5.5, and subsequently incubated in 10 mM sodium
periodate on ice for 20 min. Oocysts were then washed three
times with PBS containing 0.1% bovine serum albumin (BSA;
Sigma-Aldrich). To release the sporozoites from the oocysts
(excystation), parasites were incubated in DMEM containing
0.75% sodium taurocholate (Sigma-Aldrich) at 37◦C for 30 min
or until 50% excystation was determined by microscopy. Then,
sporozoites from 1 × 105 oocysts were inoculated in each
well. Non-infected cells incubated with supplemented DMEM
served as negative controls as well as infected cells incubated
with supplemented DMEM, as positive controls. OlPC was
serially diluted in supplemented DMEM and was subsequently
added to each well at concentrations ranging from 10 pM
to 100 μM (4.33 pg/mL to 43.3 μg/mL). Miltefosine and
paromomycin, diluted in supplemented DMEM, were also tested
at concentrations ranging from 10 pM to 10 μM (4.08 pg/mL to
4.08 μg/mL) and 10 pM to 100 μM (7.14 pg/mL to 71.4 μg/mL)
respectively, to serve as controls. Plates were further incubated
for 48 h at 37◦C with 5% CO2. In vitro assays were run two
independent times and each condition was run in triplicate
for the miltefosine assay and in duplicate for the OlPC and
the paromomycin assays. At the completion of the incubation,
supernatants were removed and cells were lifted using 0.25%
trypsin in EDTA (Wisent). To assess parasite burden in each well
and determine the eﬃcacy of OlPC, miltefosine or paromomycin
against C. parvum, DNA was extracted from samples using
QIAampDNAMini Kit (Qiagen, Toronto, ON, Canada). Puriﬁed
DNA was stored at −20◦C until use.
Quantitative Polymerase Chain Reaction
Primers, Probe, and Standard Curve
Parasite burden from DNA samples from in vitro assays as
well as from mouse fecal and intestinal samples were assessed
by quantitative polymerase chain reaction (qPCR) targeting
the hsp70 gene of C. parvum (GenBank: U69698.2) using
the LightCycler 2.0 system (Roche, Laval, QC, Canada).
Primers and probe sequences (TaqMan) were used according to
previously published sequences (Shahiduzzaman et al., 2009).
Brieﬂy, a master mix per sample was prepared by adding
5 μL of PCR-grade water (Roche), 2 μL of 10 μM of forward
primer (CP_hsp70_fwd: 5′-AACTTTAgCTCCAgTTgAgAAA
gTACTC-3′; Tib MolBiol, Adelphia, NJ, USA), 2 μL of 10 μM
reverse primer (CP_hsp70_rvs: 5′-CATggCTCTTTACCgTTA
AAgAATTCC-3′; MolBiol), 2 μL of 2 μM 5′ 6-carboxy
ﬂuorescein reporter dye (FAM) probe with a 3′ tetramethylrh
odamine quencher dye (TMR; hsp-taq: 5′-AATACgTgTAgAAC
CACCAACCAATACAACATC-3′; MolBiol), and 4 μL of buﬀer
mix containing dNTP, MgCl2, and Taq-polymerase (Roche).
Prior to the polymerase chain reaction, 5μL of sample and 15 μL
of master mix were added to LightCycler capillaries (Roche).
The initial denaturation step was conducted at 95◦C for 15 min
followed by 45 cycles of denaturation at 94◦C for 15 s and
annealing at 60◦C for 1 min (Shahiduzzaman et al., 2009).
In order to quantify parasite burden, a standard curve
was necessary. First, C. parvum oocysts were diluted to
concentrations of 1 × 101 to 1 × 106 in 200 μL and then, they
were disrupted by ﬁve freeze-thaw cycles of 2 min incubation
in liquid nitrogen followed by 2 min incubation in a 56◦C
water bath. Second, DNA from the oocyst extracts was puriﬁed
using QIAamp DNA Blood Mini Kit (Qiagen) and these samples
were run (qPCR) in the LightCycler 2.0; qPCR was used to
correlate threshold cycle values (Ct values) to parasite burden
(R2 = 0.9989). This standard curve was used to extrapolate
parasite burden from DNA samples from in vitro assays as well
as from mouse stool and intestine samples.
Immunocompromised Mouse Model of
C. parvum Infection
Cryptosporidium parvum oocysts in 2.5% K2Cr2O7 were washed
three times with PBS; parasites were then counted using a
hemocytometer and diluted in PBS to a concentration of
4 × 104/mL. Six to eight week old C57BL/6 IFNγR-KO female
and male mice (Jackson Laboratories, Bar Harbor, ME, USA)
were infected with a lethal dose of 4000 oocysts in 100 μL
of PBS on Day 0 using a 22-gage gavage needle (CDVM, St-
Hyacinthe, QC, Canada).Mice were separated in eight groups (13
mice/group for treated groups and 4–8 mice/group for control
groups). Groups 1 and 2 were non-infected controls, treated
per os (oral gavage) with PBS or with 40 mg/kg/day of OlPC,
respectively. Group 3 was infected and treated with PBS (positive
controls). Groups 4–6 were infected and treated per os with
40, 30, and 20 mg/kg/day of OlPC, respectively. Groups 7 and
8 were infected controls treated per os with 10 mg/kg/day of
miltefosine and 100 mg/kg/day of paromomycin, respectively.
Treatment started at Day 3 and continued for 10 days. OlPC and
control drugs were prepared fresh on a daily basis for the length
of the treatment. Mice were weighted daily. Starting on Day 4,
individual stool samples were collected every 3–4 days until study
termination.
Five mice from each group were sacriﬁced at Day 10 (before
daily treatment) to assess and compare disease progression. Other
mice were maintained until study termination (Day 30) unless
they were found dead or had to be sacriﬁced due to severe
illness. Because of the lethality of this model (von Oettingen
et al., 2008; Ndao et al., 2013) an objective mouse rating
system based on symptom severity and behavioral changes was
developed in accordance with the Animal Care Committee and
the Canadian Council on Animal Care (CCAC) guidelines to
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determine when mice should be sacriﬁced due to illness. Upon
death or euthanasia, the mouse ileum was preserved in formalin
for histological purposes and the rest of the intestine (duodenum
to rectum) was collected individually and chopped into 0.5 cm
pieces into a 60mL specimen container (ThermoFisher Scientiﬁc,
Ottawa, ON, Canada) with 10 mL of 0.02% (v/v) Tween20 in
PBS (one container per mouse). During necropsy, stool was also
collected for oocyst puriﬁcation.
After completion of the in vivo study, a constant volume
of puriﬁed oocysts from intestinal samples of mice from
each treatment groups was inoculated to naïve C57BL/6
IFNγR-KO mice to determine if the concentration of
oocysts remaining in the intestines of treated mice was
able to induce clinical signs of cryptosporidiosis in naïve
mice.
All mouse studies were conducted at the Montreal General
Hospital rodent animal facility site of the Research Institute
of McGill University Health Center. All studies performed
were approved and in accordance with the MGH Facility
Animal Care Committee and also in accordance with the CCAC
guidelines.
Oocyst Purification from Intestinal Samples
and Oocyst Burden Analysis by qPCR
For each mouse intestine sample in 0.02% (v/v) Tween20
in PBS, 0.05 g of sputasol (dry mixture of 10% DTT, 76%
NaCl, 2% KCl, 10% Na2HPO4, and 2% KHPO4) was added.
Oocyst puriﬁcation was performed using a previously described
method reported in literature and by our lab (Meloni, 1996; von
Oettingen et al., 2008). Brieﬂy, each sample was homogenized
for 2 min at 7000 rpm with the Polytron PT3000D homogenizer
(Kinematica, Lucerne, Switzerland). Between each sample, the
homogenizer was cleaned with bleach and ethanol to avoid cross-
contamination. Samples were placed on a rotary mixer at low
speeds for 90 min at room temperature. Samples were then
transferred to 50 mL Falcon tubes (BD Falcon, Franklin Lakes,
NJ, USA) and centrifuged at 2000 × g for 10 min at 4◦C. The
supernatant was removed and the pellet was resuspended in
8 mL of 0.02% (v/v) Tween20 in ddH2O and 2 mL of diethyl
ether (Sigma-Aldrich, Oakville, ON, Canada). Samples were
thoroughly vortexed and centrifuged at 2000 × g for 10 min
at 4◦C. The layers containing fatty cells and tissues as well as
the supernatants were removed. The pellets were washed with
20 mL of cold ddH2O and centrifuged at 2000 × g for 10 min
at 4◦C. Supernatants were discarded and the pellets resuspended
in 20 mL of saturated NaCl. Samples were vortexed thoroughly,
carefully overlayed with 5 mL of cold ddH20 and centrifuged at
2000 × g for 10 min at 4◦C. Five milliliters of the interphase
were collected and centrifuged at 2000 × g for 10 min at 4◦C;
supernatants were discarded and oocyst-containing pellets were
resuspended in 1 mL PBS containing 10 μg/ml streptomycin and
100 U/ml penicillin. Puriﬁed oocyst samples were stored at 4◦C.
For qPCR analysis, 200 μL were taken from each puriﬁed oocyst
sample and ﬁve freeze/thaw cycles of 2 min incubation in liquid
nitrogen followed by 2 min incubation in a 56◦C water bath were
performed. DNA was then extracted using the QIAamp DNA
BloodMini Kit (Qiagen) and samples was used for qPCR analysis.
Oocyst Purification from Stool Samples and
Oocyst Shedding Analysis by qPCR
Individual stool samples were collected in 500 μL of distilled
and deionized (18.2 M cm) water (ddH2O) and stored in
microcentrifuge tubes at 4◦Cuntil used. Samples were thoroughly
vortexed until stools were homogenized to smaller particles,
then centrifuged at 14000 × g and washed with cold ddH2O.
Supernatants were discarded and the pellets resuspended in 1 mL
of saturated NaCl. Samples were vortexed thoroughly, carefully
overlayed with 250μL of cold ddH2O and centrifuged at 1600× g
for 10 min at 4◦C. All of the supernatant was collected and
the sample was exposed to another NaCl-ddH2O overlay. The
supernatants collected from both overlays were centrifuged at
14000 × g for 3 min at 4◦C, combined into one tube and
resuspended in 200 μL of ddH2O. Puriﬁed oocysts were exposed
to ﬁve freeze/thaw cycles as described above. DNA was extracted
using the QIAamp DNA Blood Mini Kit and stored at −20◦C
until oocyst shedding was quantiﬁed by qPCR. Values were
normalized by gram of stool.
Oocyst Burden Analysis by Flow Cytometry
All oocyst samples puriﬁed from mouse intestine were incubated
in a ﬁnal concentration of 1% paraformaldehyde for 15–
30 min prior to analysis. Brieﬂy, 40 ul of sample and 50 ul of
CountBrightTM absolute counting beads (Invitrogen, Burlington,
ON, Canada) were added to a paraformaldehyde solution
for a ﬁnal volume of 500 ul. Oocysts within each sample
were quantiﬁed by morphology (FSC-A and SSC-A) using BD
LSRFortessaTM cell analyser (BD, Franklin Lakes, NJ, USA).
Oocysts were initially identiﬁed with a FITC-labeled mouse
IgG3 monoclonal antibody targeting a surface antigen (AbD
Serotec, Raleigh, NC, USA). Results demonstrated that 98% of the
FITC positive events occupied a distinct population by size and
complexity in the FSC-A and SSC-A channels. Results generated
by ﬂow cytometry are based on unstained samples gating on this
distinct oocyst population. Oocyst concentration per sample was
calculated by determining the quantity of sample collected based
on the number of CountBrightTM bead events collected. Final
oocyst numbers were normalized by gram of mouse intestines.
Histopathology
Cryptosporidium parvum is known to preferentially infect
the jejunum and ileum (Fayer and Xiao, 2008), thus the
ileum was collected for histopathology. Liver and spleen
were also ﬁxed in formalin, paraﬃn-embedded and cut to
4 μm thick sections. Sections were stained with hematoxylin
and eosin to further assess disease progression by light
microscopy.
Data Analysis
All in vitro studies and qPCR data were analyzed using Microsoft
Excel (Microsoft Corporation, Redmond, WA, USA). Graphs
and P-values were obtained using GraphPad Prism R© version 6.0
(GraphPad Software, Inc., La Jolla, CA, USA). Results represent
mean ± standard error mean (SEM). For OlPC and miltefosine
EC50 calculations, the same software, GraphPad Prism R© version
6.0, the non-linear ﬁt of EC50 shift and the “shared value for
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all data sets” constraint for Bottom and Top were used. Flow
cytometry data was analyzed using FlowJo v10 analytical software
(Treestar, Inc., San Carlos, CA, USA).
Results
OlPC and Miltefosine Inhibit C. parvum
Infection in HCT-8 Cells In Vitro
To test the eﬃcacy of OlPC to inhibit C. parvum infection in
vitro, we used HCT-8 cells which allowed the parasite to replicate
(Widmer et al., 2000). Miltefosine was used as a control as its
eﬃciency to inhibit C. parvum infection in vitro has already been
described (Shahiduzzaman et al., 2009). However, the dose of
100 μM was not tested for miltefosine as cell toxicity has been
reported at a concentration of 24.5 μM when cells are incubated
for 45 h (Shahiduzzaman et al., 2009). For the OlPC and the
miltefosine assays, DNA was extracted after 48 h of incubation
with the compound. A standard curve was used to correlate
threshold cycle values (Ct values) obtained by qPCR to parasite
burden. Then, for each well, the percentage of parasite burden
reduction was assessed according to this formula:
=[1-(parasite burden from tested well/parasite burden of
positive control)]∗100
Positive controls were infected cells incubated with
supplemented media (no compound). Figure 1 represents
the mean of the parasite burden reduction of tested wells for each
concentration of OlPC (A) and miltefosine (B) ± SEM.
HCT-8 cells treated with 100, 10, and 1 μM of OlPC
showed the highest C. parvum inhibition with 87, 84, and 85%
reduction in parasite burden, respectively (Figure 1A). Therefore,
these concentrations of OlPC are not statistically diﬀerent than
uninfected controls showing the clear potency of these treatments
to inhibit C. parvum infection in vitro. There is a statistical
diﬀerence (P < 0.0001) between OlPC treatment and uninfected
controls starting at the concentration of 100 nM due to the
lack of eﬃciency of these doses to inhibit C. parvum infection.
Results demonstrated a dose-dependent reduction of C. parvum
burden when treated with increasing concentrations of OlPC and
a calculated EC50 of 18.84 nM. Cell toxicity of OlPC was not
observed at concentrations of ≤50 μM using an XTT assay (data
not shown).
Miltefosine at concentrations of 10 and 1 μM showed
the highest inhibitory eﬀect with 85 and 69% reduction in
parasite burden, respectively (Figure 1B). Similarly to the
OlPC treatment, at these concentrations, there is no statistical
diﬀerence between themiltefosine treatment and uninfected cells.
So, OlPC is as potent as miltefosine at inhibiting C. parvum
infection in vitro at a concentration of 10 μM (84 vs. 85%), but
OlPC better inhibits infection at a concentration of 1 μM (85 vs.
69%). The calculated EC50 for miltefosine is 0.81 μM, which is
slightly lower than the previously published value of 1.87 μM for
this compound and this parasite (Shahiduzzaman et al., 2009),
but within the same range. Batch diﬀerences in oocyst virulence
due primarily to freshness are normal and can explain this type of
variation. Concentrations of paromomycin ranging from 10 pM
to 100 μMwere tested to determine the ability of this compound
to inhibit C. parvum infection in vitro. However, no signiﬁcant
eﬀect was observed (data not shown), which is in agreement with
what has been published previously (Ndao et al., 2013).
OlPC shows a Dose-Dependent Effect on
C. parvum-Induced Mortality in an
Immunodeficient Mouse Model
The C57BL/6 IFNγR-KO mouse model is an excellent model
to assess the eﬃcacy of compounds to treat acute C. parvum
infection because of the high susceptibility of these knockout
mice to this parasite (von Oettingen et al., 2008; Ndao et al.,
2013). According to previous reports, mice infected with as low
as 1500 oocysts had a mortality rate of 80% by Day 14 (Ndao
et al., 2013). Therefore, in this study, mice were infected with
4000 oocysts, and survival, as well as parasite burden reduction,
was used to diﬀerentiate an eﬀective treatment from an ineﬃcient
treatment. To ensure the objectivity of the study, an external
blinded examiner scored the mice reaching pre-deﬁned critical
clinical end-points according to a pre-established rating system.
As expected, infected controls started showing symptoms of
illness as early as Day 5 and had a very high mortality rate
at Day 14. For the PBS treated group, mice started showing
signs of illness (such as hunched back, weight loss, dehydration,
lethargy, and watery stools) at Day 5 and all mice from this
group died or were euthanized between Days 6 and 10 (Figure 2).
Mice treated with 100 mg/kg/day of paromomycin for 10 days
displayed clinical symptoms of cryptosporidiosis at Day 7 and a
60% mortality rate was observed at Day 9. Some paromomycin-
treated mice did survive until Day 13 but, the Mantel-Cox or
the Gehan–Breslow–Wilcoxon tests used to compare survival
curves showed no signiﬁcant diﬀerence with the PBS-treated
group (Figure 2).
Mice treated with 10 mg/kg/day of miltefosine, the analog
of OlPC, also showed signs of illness as early as Day 7 and a
50% mortality rate at Day 13 but, survivors remained alive until
the end of the study (Day 30; Figure 2).This clear diﬀerence
in survival rates with the PBS-treated group (P < 0.001)
determined that a 10mg/kg/daymiltefosine treatment for 10 days
signiﬁcantly decreased mortality. Nevertheless, at Day 30, clinical
signs of cryptosporidiosis were still visible in these mice such as
15% weight loss, hunched backs, dehydration, and soft stools.
Mice treated with 40 mg/kg/day of OlPC displayed a 100%
survival rate by the experimental endpoint (Day 30; P < 0.001;
Figure 2). Additionally, the onset of symptoms began later (Day
9) than the PBS-treated controls; clinical signs were less severe
and did not last as long in comparison with other groups.
Furthermore, at Day 10, which is the peak of infection (von
Oettingen et al., 2008), weight loss (about 10% reduction from
initial weight for the 40 mg/kg/day OlPC-treated group) was
already signiﬁcantly lower compared to any of the infected
control groups (>15% of initial weight, P < 0.05, data not
shown). By Day 30, 40 mg/kg/day OlPC-treated mice looked
healthy as they displayed no visible signs of illness. Moreover,
unlike the miltefosine-treated group, 40 mg/kg/day OlPC-treated
mice had exceeded, by Day 30, their initial weights (P < 0.0001,
data not shown). Mice treated with 30 mg/kg/day of OlPC for
10 days, had less severe clinical signs of cryptosporidiosis. For
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FIGURE 1 | Efficacy of OlPC and miltefosine in vitro. (A) Parasite burden reduction in HCT-8 cells after 48 h incubation with different concentrations of OlPC.
(B) Parasite burden reduction in HCT-8 cells after 48 h incubation with different concentrations of miltefosine. Error bars were calculated as ±SEM (∗∗∗∗P < 0.0001).
these latter mice, on one hand, treatment was not able to rescue
all mice which showed a severe weight loss of up to 15% of
initial weight; on the other hand, the onset of symptoms was
delayed to Days 8 or 9. Their survival rate was of 87.5% at Day
11, 75% at Day 30 (Figure 2) and, by Day 30, the survivors
displayed no visible signs of illness and had returned to their
initial weights (data not shown). Finally, the lowest dose of OlPC
(20 mg/kg/day) was still able to rescue 75% of mice at Day 30
even if there were still visible signs of illness and mice had a 5%
weight loss in comparison with initial weights. Non-infected mice
treated with 40 mg/kg/day of OlPC presented a constant weight
through the length of the study and no clinical sign were noted in
this group (data not shown).
OlPC Eliminates Oocyst Shedding in a
Dose-Dependent Manner
All infected mice began shedding oocysts between Days 5 and
7. Stool samples were collected from individual mice, processed
and analyzed by qPCR. At Day 10, infected mice treated with
PBS and with 100 mg/kg/day of paromomycin were shedding
8.52 × 107 and 1.84 × 108 oocysts per gram of stool (oo/g
of stool) respectively (data not shown). Similarly, mice treated
with 10 mg/kg/day of miltefosine were shedding 1.94 × 108 oo/g
of stool at Day 10 (Figure 3). At Days 14 and 30, surviving
mice of this group continued to shed considerable levels of
oocysts; 1.49 × 107 and 1.5 × 107 oo/g of stool respectively
(Figure 3).
In mice treated with 40 mg/kg/day of OlPC, oocyst shedding
reduction occurred as early as Day 10 with only 7.59 × 106
oo/g of stool which is a signiﬁcant reduction in comparison
with the 10 mg/kg miltefosine group (P < 0.01; Figure 3). At
Day 14, after 10 days of OlPC-treatment, oocyst shedding in
this group was even lower with 5.14 × 103 oo/g, representing a
99.96% reduction (4-log reduction) in oocyst shedding. At Day
14, the 40 mg/kg/day OlPC-treated group is also statistically
diﬀerent when compared with the 10 mg/kg miltefosine-treated
mice (P < 0.05; Figure 3). Finally, at Day 30, there was a
100% elimination of oocyst shedding (>7-log reduction) in all
mice of the 40 mg/kg/day OlPC-treated group (P < 0.0001;
Figure 3). Light microscopy was used to conﬁrm qPCR results.
Indeed, all the samples of 40 mg/kg/day OlPC-treated mice at
Day 30 were negative as no oocysts could be visualized under the
microscope.
Mice treated with 30 mg/kg/day of OlPC showed a similar
tendency in oocyst shedding as the 40 mg/kg/day OlPC-treated
group. Eﬀectively, all average oocyst counts were signiﬁcantly
FIGURE 2 | Survival curves in C57BL/6 IFNγR-KO mice infected with
C. parvum. Results are shown in a survival curve. Results do not include
mice sacrificed at Day 10 for disease progression analysis. On Day 30
remaining mice were sacrificed along with uninfected controls.
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FIGURE 3 | Oocyst shedding in C57BL/6 IFNγR-KO mice infected with C. parvum. All stool samples were collected from individual mice within each group,
processed and analyzed by qPCR. Results were normalized to shed oocysts per grams of stool. Error bars were calculated as ±SEM (∗P < 0.05, ∗∗P < 0.01, and
∗∗∗∗P < 0.0001).
lower when compared with the 10 mg/kg/day miltefosine-treated
group (Figure 3); at Day 10, the average oocyst shedding was
2.45 × 106 oo/g of stool (P < 0.0001), at Day 14, 4.9 × 102 oo/g
of stool (P < 0.05) and, at Day 30, 13 oo/g of stool (P < 0.01).
Mice treated with 20 mg/kg/day of OlPC had the least important
reduction in oocyst shedding but remained signiﬁcantly lower
than the 10 mg/kg miltefosine-treated mice. In fact, 4.04 × 107,
3.68 × 105, and 5.95 × 103 oo/g of stool, was evaluated in these
20 mg/kg/day OlPC-treated mice at Day 10 (P < 0.01), Day 14
(P < 0.01), and Day 30 (P < 0.05) respectively (Figure 3).
Oocyst shedding was not statistically diﬀerent between mice
treated with 30 mg/kg/day and 40 mg/kg/day at Days 10 and
14. The fact that the numerical value of the mean for parasite
burden/g of stool for the 40 mg/kg/day treated mice was slightly
higher at Days 10 and 14 than the one for 30 mg/kg/day treated
mice is most probably due to inter-individual variations in this
mouse model.
OlPC Significantly Reduces Parasite Burden in
the Intestines of C57BL/6 IFNγR-KO Mice
Infected with C. parvum
To quantitate parasite and oocyst burden in the intestines and
assess disease progression of infected mice during and after
their respective treatments, mice were euthanized and intestines
were collected at two time points: Days 10 or 30. Intestinal
samples from every mouse were processed individually to purify
C. parvum parasites, analyzed using qPCR and normalized to
parasites per gram of intestines (p/g of intestines). On Day 10,
infected control groups revealed massive levels of C. parvum in
the gut. Mice treated with PBS had the highest parasite burden
with 4.77 × 107 p/g of intestines followed by mice treated with
100 mg/kg/day of paromomycin with 5.01 × 106 p/g of intestines
(Figure 4A). Mice treated with 10 mg/kg/day of miltefosine also
had very high parasite burden with 7.94 × 106 p/g of intestines
(Figure 4A). In mice treated with OlPC, parasite burden was
signiﬁcantly lower compared to the infected PBS control group.
After 7 days of treatment (Day 10), 20 mg/kg/day OlPC-treated
mice showed a parasite burden of 3.44 × 106 p/g of intestines
(P < 0.01; Figure 4A). In mice treated with 30 mg/kg/day of
OlPC the parasite burden was even lower with 1.81 × 105 p/g of
intestines (P < 0.001) corresponding to a 99.6% (2-log reduction)
parasite burden reduction in comparison with the PBS control
group (Figure 4A). Similarly, mice treated with 40 mg/kg/day of
OlPC also revealed a 99.6% reduction in parasite burden with
2.25 × 105 p/g of intestines (P < 0.001) when compared to the
infected PBS control mice (Figure 4A).
By Day 30, 17 days after the completion of the treatments,
surviving mice treated with 10 mg/kg miltefosine exhibited
a high parasite burden with 2.65 × 106 p/g of intestines
(Figure 4B). Parasite burden decreased in mice treated with
OlPC when compared to the 10 mg/kg miltefosine-treated
mice following a dose-dependent response. Indeed, in mice
treated with 20 mg/kg/day of OlPC, parasite burden obtained
was 1.09 × 105 p/g of intestines (not signiﬁcant, P > 0.05),
whereas in mice treated with 30 mg/kg/day and 40 mg/kg/day,
parasite burden was 4.66 × 103 p/g of intestines (99.8% parasite
burden reduction, P < 0.05) and 692 p/g of intestines (99.97%
parasite burden reduction, P < 0.01) respectively (Figure 4B).
Additionally, by Day 30 there was an overall reduction in parasite
burden in each group compared to their burden at Day 10.
To cross-validate results obtained by qPCR and to conﬁrm the
presence of C. parvum oocysts in the intestines, ﬂow cytometry
was used to quantify the number of oocysts per gram of intestines
(oo/g of intestines). Flow cytometry data analysis allowed to
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FIGURE 4 | Parasite and oocyst burden in C57BL/6 IFNγR-KO mice infected with C. parvum. All intestinal samples were analyzed by qPCR represented by
the clear bars and by flow cytometry represented by the checkered bars. qPCR results were normalized to parasites per gram of intestines and flow cytometry
results were normalized to oocysts per gram of intestines. (A) Parasite and oocyst burden in mice at Day 10. (B) Parasite and oocyst burden in mice at Day 30. Error
bars were calculated as ±SEM.
identify oocysts by their size and morphology (FSC-A and SSC-
A) and to count them for each intestinal sample. In general,
total parasite burdens calculated by ﬂow cytometry were lower
than those obtained by qPCR suggesting the presence of other
stages of the parasite in the intestines that ﬂow cytometry cannot
distinguish. However, the results were supportive of those of
the qPCR. Mice treated with PBS, 100 mg/kg paromomycin and
10 mg/kg miltefosine showed an oocyst burden of 1.46 × 106
oo/g of intestines, 2.3 × 105 oo/g of intestines and 4.53 × 105
oo/g of intestines respectively (Figure 4A). In mice treated
with 20 mg/kg/day of OlPC, 9.4 × 104 oo/g of intestines
was detected which consisted in a 93.5% decrease in oocyst
burden compared to the PBS treated group (P < 0.01). The
reductions in oocyst burden increase in mice treated with 30
or 40 mg/kg/day of OlPC were only 180 oo/g of intestines
(99.98% reduction, P < 0.01) and 167 oo/g of intestines (99.98%
reduction, P < 0.01) respectively (Figure 4A). In both cases an
average 4-log reduction in oocyst burden was observed when
compared to PBS treated mice. In surviving mice treated with
10 mg/kg miltefosine, oocyst burden at Day 30 was 1.4 × 105
oo/g of intestines which is comparable to their oocyst burden at
Day 10 (Figures 4A,B). At Day 30, at 20 mg/kg/day of OlPC,
oocyst levels were slightly lower (6.63 × 104 oo/g of intestines)
than mice treated with 10 mg/kg/day of miltefosine, but this
diﬀerence remained statistically non-signiﬁcant (52.6% oocyst
burden reduction, Figure 4B). At 30 mg/kg/day of OlPC, oocyst
burden (2.81 × 103 oo/g of intestines) increased compared to the
oocyst burden at Day 10 but still represented a 98% oocyst burden
reduction compared to the oocyst burden at Day 30 for 10 mg/kg
miltefosine-treated mice (Figure 4B). Finally, at 40 mg/kg/day of
OlPC, mice showed the lowest oocyst burden in their intestines
with 34 oo/g of intestine representing a 99.98% oocyst burden
reduction when compared to the 10 mg/kg miltefosine-treated
mice (P < 0.01, Figure 4B).
OlPC Eliminates the Presence of Oocysts in
Histological Sections of the Ileum of C57BL/6
IFNγR-KO Mice Infected with C. parvum
To visually validate the presence of C. parvum life cycle stages
in the intestines of infected mice, the ileum was collected
from all mice at time of death. Sections from the ileum were
prepared and stained (H&E) for histopathology purposes. Ileum
sections from mice treated with PBS and 100 mg/kg/day of
paromomycin at Day 10 revealed an overwhelming presence of
C. parvum life cycle stages and severe damage to the epithelium
of the intestine (Figures 5A,B). Damage to intestinal mucosa
includes blunting of the villi, acute inﬂammation and formation
of ﬁbrin (ﬁbrinous hemorrhagic enteritis) resulting from local
hemorrhage and clotting (Figures 5A,B). The ileum of mice
treated with 10mg/kg/day of miltefosine was as severely damaged
and infected as the other controls (Figure 5C). At Day 10,
C. parvum oocysts were also abundantly present in mice treated
with 20 mg/kg/day of OlPC and intestinal damage was also
present but to a lesser extent than in the infected controls
(Figure 6A). At the dose of 30 mg/kg/day of OlPC, mild intestinal
damage and inﬂammation were noticeable andC. parvum oocysts
were scarcely visible (Figure 6B). Finally, at 40 mg/kg/day,
mice displayed practically no signs of intestinal damage or
inﬂammation and a rare presence of C. parvum oocysts at Day 10
(Figure 6C). Slides from the ileum of non-infected controls were
also prepared to provide a negative reference for comparison
(data not shown).
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FIGURE 5 | Day 10 histological sections of the ileum of control
C57BL/6 IFNγR-KO mice infected with C. parvum. Representative
transverse sections of the ileum stained with H&E showing disease
progression. (A) Ileum of mice treated with PBS. Formation of fibrin is
noticeable (yellow arrow). (B) Ileum of mice treated with 100 mg/kg/day of
paromomycin. (C) Ileum of mice treated with 10 mg/kg/day of miltefosine.
(A–C) Shows severe epithelial damage and abundance of oocysts. Each
group is represented at 100 and 400x magnifications. Red arrows indicate
C. parvum oocysts.
At Day 30, the surviving mice treated with 10 mg/kg/day
of miltefosine revealed an abundant presence of C. parvum
oocysts and severe damage to the gut epithelium (Figure 7A).
At the lowest concentration of OlPC, mice displayed a moderate
presence of C. parvum oocysts and only mild damage to the
intestinal epithelium (Figure 7B). At 30 and 40 mg/kg/day of
OlPC, mice showed a complete absence of C. parvum oocysts
and a healthy ileum in comparison with controls (Figures 8A,B).
Sections of ileum, liver and spleen (data not shown) were also
processed in uninfected (control) mice treated with 40mg/kg/day
for 10 days and no inﬂammation or toxicity was noticeable.
Residual Infectious Oocyst Concentration from
Mice Exposed to OlPC is not Sufficient to
Cause a New Infection in Naïve C57BL/6
IFNγR-KO Mice
Another experiment was conducted to determine whether there
was a suﬃcient number of infectious oocysts (more than the
minimal infectious dose) remaining in the intestines of surviving
mice at Days 10 or 30 to transmit the parasite and cause a
new infection. To do so, naïve C57BL/6 IFNγR-KO mice were
FIGURE 6 | Day 10 histological sections of the ileum of OlPC-treated
C57BL/6 IFNγR-KO mice infected with C. parvum. Representative
transverse sections of the ileum stained with H&E showing disease
progression. (A) Ileum of mice treated with 20 mg/kg/day of OlPC shows
significant epithelial damage and abundance of oocysts. (B) Ileum of mice
treated with 30 mg/kg/day of OlPC. (C) Ileum of mice treated with
40 mg/kg/day of OlPC. Sections from (B,C) reveal mild gut epithelial damage
and rare presence of oocysts. Each group is represented at 100 and 400x
magnifications. Red arrows indicate C. parvum oocysts.
infected with a constant volume of the puriﬁed oocysts from
mouse intestinal samples coming from the diﬀerent treatment
groups from both Days 10 and 30. In order to determine if
naïve mice were infected, stool samples were taken once a week,
processed and analyzed by qPCR and light microscopy (Table 1).
Presence of C. parvum oocysts or DNA in the stool of these naïve
mice suggests that a fully complete life cycle was achieved by the
parasite. Therefore, the concentration of infectious oocysts in the
puriﬁed intestinal samples of mice from the in vivo study would
be considered to cause a new infection. Results demonstrated that
only the puriﬁed intestinal samples from 40 mg/kg/day OlPC-
treated mice at Day 30 were not able to successfully transmit
a C. parvum infection in naïve C57BL/6 IFNγR-KO mice. For
these inoculated naïve mice, no oocysts could be seen by light
microscopy and no DNA could be detected by qPCR in the stool
even by Day 35 (Table 1). Additionally, no sign of illness were
observed and the histological sections of the ileum revealed a
complete absence of oocysts (data not shown). This observation
corroborates previous results as 40mg/kg/day OlPC-treated mice
have been shown to have practically cleared the infection at D30.
However, naïve C57BL/6 IFNγR-KO mice infected with puriﬁed
intestinal samples from other treatment groups developed signs
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FIGURE 7 | Day 30 histological sections of the ileum of control and
20 mg/kg/day OlPC-treated C57BL/6 IFNγR-KO mice infected with
C. parvum. Representative transverse sections of the ileum stained with H&E
showing disease progression. (A) Ileum of mice treated with 10 mg/kg/day of
miltefosine shows severe epithelial damage and abundance of oocysts.
(B) Ileum of mice treated with 20 mg/kg/day of OlPC shows some epithelial
damage and moderate level of oocysts. Each group is represented at 100 and
400x magnifications. Red arrows indicate C. parvum oocysts.
FIGURE 8 | Day 30 histological sections of the ileum of 30 mg/kg/day
OlPC-treated and 40 mg/kg/day OlPC-treated C57BL/6 IFNγR-KO
mice infected with C. parvum. Representative transverse sections of the
ileum stained with H&E showing disease progression. (A) Ileum of mice
treated with 30 mg/kg/day of OlPC. Section reveals no gut epithelial damage
and an absence of oocysts. (B) Ileum of mice treated with 40 mg/kg/day of
OlPC presents no sign of epithelial damage and an absence oocysts. Each
group is represented at 100 and 400x magnifications.
of cryptosporidiosis. By Day 17, these inoculated naïve mice
exhibited signs of illness (hunched back, weight loss, dehydration,
lethargy, and watery stools). Moreover, oocysts could be seen by
light microscopy and detected by qPCR (Table 1). Histological
sections revealed a heavy presence of C. parvum oocysts and
severe damage to the microvilli (data not shown). These results
suggested that the oocysts in the puriﬁed intestinal samples of the
other groups were suﬃcient to transmit C. parvum to a new host
and cause acute cryptosporidiosis.
Discussion
Cryptosporidium parvum is a recognized threat to public health
(Guerrant, 1997; Feldmann et al., 2002) and has been reported
in more than 40 countries in all ﬁve continents (Putignani and
Menichella, 2010). Many waterborne outbreaks reported in the
past decade do not limit C. parvum infection to developing
countries, but have been reported in Canada, USA, Sweden,
and France as a result of tap water contamination (Putignani
and Menichella, 2010). On one hand, Cryptosporidium causes
persistent diarrhea and stunting in young children (Putignani
and Menichella, 2010; Bouzid et al., 2013; Richard et al., 2014;
Shikani and Weiss, 2014) and, on the other hand, AIDS patients
can develop a chronic infection that can be fatal (Chen et al.,
2002; Chalmers and Davies, 2010; Bouzid et al., 2013; Mead
and Arrowood, 2014). The major issue comes from the lack
of eﬃcacious treatment options for cryptosporidial infections
(Mead and Arrowood, 2014).
In this present study, we addressed the need for a new
eﬃcacious treatment against cryptosporidiosis by testing the
compound OlPC, an alkylphosphocholine drug, already in
clinical development against leishmaniasis. As a close analog
of miltefosine, a drug recently approved by the FDA to treat
cutaneous, mucosal and visceral leishmaniasis (FDA, 2014) and
to treat primary amebic meningoencephalitis (CDC, 2013), OlPC
is suspected to share a similar mode of action by interfering
with parasitic lipid biosynthesis and cellular membrane integrity
while inducing apoptosis of the parasite (Dorlo et al., 2012).
Repurposing OlPC as an anti-cryptosporidiosis drug would have
several advantages as the safety of this compound is already
reported and pharmacological as well as pharmacokinetics
studies are already ongoing (Fortin et al., 2012).
Initial in vitro results demonstrated that OlPC eﬃciently
inhibits C. parvum infection of HCT-8 cells after 48 h exposure
to the drug. OlPC reduced parasite burden by 84% at ≥10 μM
and exhibited signiﬁcant activity down to 10 nM with an EC50 of
18.84 nM. We report here that the concentrations used for OlPC
and miltefosine to achieve a signiﬁcant reduction in C. parvum
infectivity were far lower than the one published in the literature
for paromomycin (EC50 of 711 μM), the currently used drug
against cryptosporidiosis in AIDS patients (Armson et al., 1999;
Downey et al., 2008). The toxicity proﬁle displayed by OlPC was
also very low with a 40% reduction in host cell viability only
at 100 μM and higher. Conversely, it was reported that HCT-
8 cells presented signs of toxicity when exposed to miltefosine
for 48 h at concentrations as low as 24.5 μM (Shahiduzzaman
et al., 2009). Therefore, OlPC surpasses miltefosine in regards to
its safety in host cells. Even though many drugs have been shown
to successfully inhibit C. parvum infection in vitro, many of them
have failed to inhibit cryptosporidiosis in an animal model (Mead
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TABLE 1 | Infectivity of purified intestinal samples from the in vivo study in naïve C57BL/6 IFNγR-KO mice.
Day 10b Day 17b Day 35b
Treatmenta Microscopy qPCR Microscopy qPCR Microscopy qPCR
PBS Day 10 Yes Yes - - - -
Day 30 - - - - - -
100 mg/kg of paromomycin Day 10 Yes Yes - - - -
Day 30 - - - - - -
10 mg/kg of miltefosine Day 10 Yes Yes - - - -
Day 30 No No Yes Yes - -
20 mg/kg of OlPC Day 10 Yes Yes - - - -
Day 30 No No Yes Yes - -
30 mg/kg of OlPC Day 10 Yes Yes - - - -
Day 30 No No Yes Yes - -
40 mg/kg of OlPC Day 10 No No No Yes - -
Day 30 No No No No No No
aTreatment given to mice during the in vivo study. Purified intestinal samples from these mice at Days 10 or 30 were used to infect naïve C57BL/6 IFNγR-KO mice.
bRepresents the day post-inoculation that the stool from naïve mice was collected. The presence of C. parvum oocysts or its DNA in the stool of naïve mice is scored
qualitatively. Dashes represent no available data due to mouse mortality during study: either there was no purified intestinal sample available to inoculate naïve mice (i.e.,
no PBS-treated mice in the in vivo study survived until Day 30) or naïve mice died during rechallenge study (no naïve mice inoculated with purified intestinal samples from
mice treated with miltefosine survived until stool collection on Day 35).
and Arrowood, 2014). Such is the case for monensin (Blagburn
et al., 1991) and paromomycin which only started to show eﬃcacy
in dexamethasone immunosuppressed mice at very high doses
of 1 g/kg/day (Healey et al., 1995). Because the action of the
drugs on C. parvum parasites is more direct when tested in vitro
than in an animal model, it is possible that the results from the
former does not translate to the latter (Mead and Arrowood,
2014). In fact, many factors inﬂuence the eﬀect of drugs in vivo
on pathogens such as its bioavailability, pharmacodynamics and
pharmacokinetics as well as food and drug interactions. Thus,
it is important to understand the limitations of the C. parvum
in vitro model to mimic an in vivo model of infection and we
must acknowledge in vitro results only as informative precursors
to further investigations in animal models.
Therefore, to determine whether the in vitro activity of OlPC
on C. parvum could be translated in vivo, we decided to use
C57BL/6 IFNγR-KO mice, an animal model highly susceptible
to C. parvum infection (You and Mead, 1998; von Oettingen
et al., 2008). Unlike other immunocompromised animal models
where a very large C. parvum inoculum must be given (such as
the dexamethasone (Yang and Healey, 1993; Healey et al., 1995),
the SCID (Mead et al., 1995; Tzipori et al., 1995), the neonatal
(Downey et al., 2008) or the malnourished models (Costa et al.,
2012), C57BL/6 IFNγR-KO mice can consistently develop severe
illness with an infectious dose of only 10 oocysts (Yang et al., 2000;
von Oettingen et al., 2008). It has also been demonstrated that
doses as low as 1000 oocysts were lethal by Days 9–14 (Mead
and You, 1998; You and Mead, 1998) and 1500 oocysts lead
to 80% death in these mice (Ndao et al., 2013). In our study,
mice received 4000 oocysts by oral gavage and began receiving
treatment at Day 3 for a period of 10 consecutive days. By
increasing the inoculum in these mice, we were able to achieve
100% mortality in PBS treated mice by Day 10 which allowed
us to clearly identify the eﬃcacy of the treatment. As early as
Day 10, major diﬀerences between mice treated with the highest
doses of OlPC (30 and 40 mg/kg/day) with other groups could
already be seen. Not only did 40 mg/kg/day of OlPC reduce
parasite and oocyst burden in the intestinal tract by 99.6 and
99.98% respectively after only 7 days of daily treatment (Day
10), it also allowed 100% of these mice to survive until the
experimental endpoint (Day 30; P < 0.001). At Day 30, parasite
and oocyst burden in the intestines of the 40 mg/kg/day OlPC-
treated group reached a 99.97 and 99.98% reduction respectively
(P < 0.001) in comparison with the 10 mg/kg miltefosine group.
These data ﬁrmly support that, even after the completion of the
treatment with OlPC, mice did not show any sign of relapse in
parasite burden or recurrence in clinical symptoms. In addition,
a complete elimination of oocyst shedding in the stools was
observed and no parasite was noticed by light microscopy of
histology section of ileum of 40 mg/kg/day OlPC-treated mice
at Day 30. In consequence, it is not surprising that puriﬁed
intestinal samples from 40 mg/kg/day OlPC-treated mice at D30
were incapable of further transmitting the infection to naïve
C57BL/6 IFNγR-KOmice. Together, this validates the hypothesis
that OlPC rescued/cured immunocompromised mice from a
lethal infection with C. parvum and, even if the 40 mg/kg/day
OlPC treatment did not completely clear infection at Day 30
(Figure 4B), it is not likely that the surviving parasites can cause
a recrudescence of infection if mice were not sacriﬁced at Day 30.
In short, we used a stringent animal model that clearly
discriminated if a drug was suﬃciently potent to rescue mice
from a lethal infection. In this model, paromomycin, given at
100 mg/kg/day for 10 days, failed to rescue mice, whereas in a
neonatal model, where the same dosage of paromomycin was
given for 6 days, it was able to reduce oocyst burden in the
distal colon by 97% and oocyst shedding by 96% (Downey et al.,
2008). However, these numbers are not corroborated by clinical
cases, where paromomycin treatments are associated with a high
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probability of relapse in AIDS patients (Hewitt et al., 2000;
Cabada and White, 2010). At lower doses, 30 and 20 mg/kg/day
of OlPC, treatments were still able to keep 75% of infected
mice alive at Day 30, but were not able to eliminate oocyst
shedding. Moreover, puriﬁed intestinal samples from these mice
were capable of transmitting the infection to other naïve C57BL/6
IFNγR-KO mice. This suggests that the dose of these OlPC
treatment regimens were not suﬃcient to eliminate C. parvum
parasites or to prevent a recurrent infection after the end of
the treatment (even though there was a 98% oocyst burden
reduction in the intestines by Day 30). Finally, miltefosine was
also tested at 10 mg/kg/day for 10 days as a control because
of the similar properties and structure it shares with OlPC.
Results demonstrated that it had modest, but signiﬁcant level
of activity against C. parvum infection since it was able to
rescue 50% of infected mice at Day 30. However, the surviving
mice were still heavily infected and presented severe signs of
illness.
No sign of discomfort or behavioral changes were noted in
infected and uninfected mice treated with 40 mg/kg/day of OlPC
for 10 days, which is supportive of data previously obtained in a
mouse model of leishmaniasis (Fortin et al., 2014). Additionally,
sections of the ileum, liver and spleen from these mice showed
no signs of toxicity or inﬂammation associated to OlPC (data not
shown).
The present study did not compare miltefosine and OlPC at
the same dosages across the entire range. While this may be
perceived as a limitation, it was reﬂective of concerns regarding
miltefosine toxicity at higher doses (FDA, 2014).
In summary, the strong activity of OlPC on C. parvum
parasites in vitrowas thoroughly supported by the outcome of the
animals in our in vivo study as OlPC rescues C57BL/6 IFNγR-
KO mice from a lethal infection of C. parvum. Data obtained
by qPCR from the in vivo study was not only cross-validated
by ﬂow cytometry and light microscopy, but was also conﬁrmed
visually by histological sections from mice ileums. Furthermore,
OlPC demonstrated, at its highest dose, a lasting eﬀect and mice
showed no sign of relapse of infection even 17 days after the end
of the treatment. As an analog of miltefosine, we hypothesize
that OlPC will have the same mechanism of action on the
parasite, that is by causing an irreversible inhibition of the
phospholipid biosynthesis pathway leading to the apoptosis in the
parasite; further studies will be needed to conﬁrm this hypothesis
(Anthony et al., 1999; Dorlo et al., 2012). Together, this
establishes OlPC as novel, consistent, sustainable, safe, and potent
anti-cryptosporidial treatment option for immunocompromised
patients.
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